Bristol-myers Squibb Stock News

Alexandria Real Estate Equities' (ARE) latest lease marks the second-largest life science lease in Alexandria's history and boosts its long-term strategic tie-up with Bristol Myers Squibb.

Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co.

Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd. , Green Cross Corp. (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc. Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd. , Green Cross Corp. (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc.

Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services.

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more fu

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address. Pharmaceutical Companies : In 2016, then- Vice President Biden launched the Cancer Moonshot program the help boost spending on medical research to take on various types of cancer. In 2022, Biden announced plans to boost spending and reduce the death rate from cancer by 50% over the next 25 years. The Partnership for Accelerating Cancer Therapies includes 11 companies working to boost treatments for various types of cancers. The companies are AbbVie Inc (NYSE: ABBV ), Amgen Inc (NASDAQ: AMGN ), Boehringer-Ingelheim Pharma , Bristol-Myers Squibb Co (NYSE: BMY ), Celgene (owned by Bristol-Myers Squibb), Genetech (owned by Roche ), Gilead Sciences (NASDAQ: GILD ), GlaxoSmithKline (NYSE: GSK ), Janssen Research (owned by Johnson & Johnson (NYSE: JNJ )), Novartis (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Pfizer Inc (NYSE: PFE ).

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells. Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn''t been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research. Another NME that passed the FDA hurdle was Sanofi''s (NASDAQ: SNY ) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.

These two biotech stocks already have blockbuster therapies that are driving increased revenue.

Bristol Myers Squibb (BMY) declares $0.54/share quarterly dividend, in line with previous.

Dragonfly receives a milestone payment from Bristol Myers Squibb for progression of its Phase 1 DF6002-001 study with a PK profile and peripheral PD consistent with preclinical models WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly") today announced…

Partners Johnson & Johnson ( JNJ , Financial) and Legend Biotech Corp. ( LEGN , Financial) would probably agree that good things come to those who wait. The two pharma companies were rewarded for thei

Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.

The FDA has accepted for review Bristol-Myers Squibb Co''s (NYSE: BMY ) supplemental application for Opdivo (nivolumab) plus chemotherapy for resectable non-small cell lung cancer (NSCLC) in a neoadjuvant setting. Under the Priority Review status, the agency has assigned a Prescription … Full story available on Benzinga.com

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.